Nautilus Biotechnology (NAUT) Liabilities and Shareholders Equity (2020 - 2026)

Nautilus Biotechnology has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $163.6 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 23.27% year-over-year to $163.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $733.4 million (down 22.26% YoY) and the FY2025 annual result came in at $191.1 million, down 21.27% from the prior year.
• Liabilities and Shareholders Equity eased to $163.6 million in Q2 2026 per NAUT's latest filing, from $177.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $384.7 million in Q1 2022 and troughed at $163.6 million in Q2 2026.
• A 5-year average of $278.0 million and a median of $280.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity soared 155.6% in 2022, then declined 23.27% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $350.1 million in 2022, then slipped by 12.71% to $305.6 million in 2023, then retreated by 20.56% to $242.7 million in 2024, then decreased by 21.27% to $191.1 million in 2025, then fell by 14.41% to $163.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $163.6 million, $177.8 million, and $191.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.